8-K filed June 7, 2023, 7:59 PM ET CIK 0001671818

other material confidence high sentiment negative materiality 0.95

Oncorus board approves dissolution plan, appoints Interim CEO and President

Oncorus, Inc.

Board approved Plan of Liquidation and Dissolution; special stockholder meeting to seek approval.
Brian Shea appointed Interim CEO and President; eligible for retention bonus of six months' base salary.
Ted Ashburn appointed Chairman, replacing Mitchell Finer; director Luke Evnin resigned from board.
Company warns trading in ONCR stock is highly speculative; stockholders may realize little value.

item 5.02 item 8.01 item 9.01

Executive movements

Machine-extracted from this filing. Every card cites the SEC source. See all recent executive movements.

Role change (interim)

Brian Shea

Interim Chief Executive Officer and President

Oncorus, Inc.

Effective: 2023-06-06
Filed: June 7, 2023, 7:59 PM ET

the Board appointed Brian Shea, age 35, the Company's General Counsel and Secretary, as the Company's Interim Chief Executive Officer and President.

Role change

Mitchell Finer

Chairman of the Board

Oncorus, Inc.

Effective: 2023-06-06
Successor: Theodore Ashburn
Filed: June 7, 2023, 7:59 PM ET

The Company thanks Dr. Finer for his years of service as Chairman and previously as Executive Chairman.

Departed

Luke Evnin

Director

Oncorus, Inc.

Effective: 2023-06-07
Filed: June 7, 2023, 7:59 PM ET

Luke Evnin, Ph.D. notified the Company of his resignation from the Board as well as the Compensation Committee and Nominating and Corporate Governance Committee of the Board, effective immediately.

Role change

Theodore Ashburn

Chairman of the Board

Oncorus, Inc.

Effective: 2023-06-06
Filed: June 7, 2023, 7:59 PM ET

the Board approved the appointment of Theodore (Ted) Ashburn, M.D., Ph.D. as Chairman of the Board, to replace Mitchell Finer, Ph.D.

Key facts

Extracted from this filing and checked against the source text.

Executive change SEC 8-K Item 5.02 confidence 0.95

Brian Shea was appointed as Interim Chief Executive Officer and President at Oncorus, Inc..

Action: appointed
Role: Interim Chief Executive Officer and President

Exact text from the filing

the Board appointed Brian Shea, age 35, the Company's General Counsel and Secretary, as the Company's Interim Chief Executive Officer and President.

View on SEC.gov

Executive change SEC 8-K Item 5.02 confidence 0.95

Mitchell Finer changed role as Chairman of the Board at Oncorus, Inc..

Action: stepped down
Role: Chairman of the Board

Exact text from the filing

The Company thanks Dr. Finer for his years of service as Chairman and previously as Executive Chairman.

View on SEC.gov

Executive change SEC 8-K Item 5.02 confidence 0.95

Luke Evnin resigned as Director at Oncorus, Inc..

Action: resigned
Role: Director

Exact text from the filing

Luke Evnin, Ph.D. notified the Company of his resignation from the Board as well as the Compensation Committee and Nominating and Corporate Governance Committee of the Board, effective immediately.

View on SEC.gov

Executive change SEC 8-K Item 5.02 confidence 0.95

Theodore Ashburn was appointed as Chairman of the Board at Oncorus, Inc..

Action: appointed
Role: Chairman of the Board

Exact text from the filing

the Board approved the appointment of Theodore (Ted) Ashburn, M.D., Ph.D. as Chairman of the Board, to replace Mitchell Finer, Ph.D.

View on SEC.gov

Source: SEC EDGAR

accession 0000950170-23-026813

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.